IMCR (Immunocore Holdings) Days Sales Outstanding : 61.28 (As of Mar. 2025)

View and export this data going back to 2021. Start your Free Trial

What is Immunocore Holdings Days Sales Outstanding?

Immunocore Holdings's average Accounts Receivable for the three months ended in Mar. 2025 was $63.1 Mil. Immunocore Holdings's Revenue for the three months ended in Mar. 2025 was $93.9 Mil. Hence, Immunocore Holdings's Days Sales Outstanding for the three months ended in Mar. 2025 was 61.28.

The historical rank and industry rank for Immunocore Holdings's Days Sales Outstanding or its related term are showing as below:

IMCR' s Days Sales Outstanding Range Over the Past 10 Years
Min: 21.01 Med: 54.8 Max: 67.72
Current: 67.35

During the past 7 years, Immunocore Holdings's highest Days Sales Outstanding was 67.72. The lowest was 21.01. And the median was 54.80.

IMCR's Days Sales Outstanding is ranked better than
52.59% of 848 companies
in the Biotechnology industry
Industry Median: 70.36 vs IMCR: 67.35

Immunocore Holdings's Days Sales Outstanding declined from Mar. 2024 (71.09) to Mar. 2025 (61.28).

Immunocore Holdings Days Sales Outstanding Historical Data

The historical data trend for Immunocore Holdings's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immunocore Holdings Days Sales Outstanding Chart

Immunocore Holdings Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Days Sales Outstanding

Get a 7-Day Free Trial

21.01

54.80

43.69

62.69

67.72

Immunocore Holdings Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Days Sales Outstanding	Get a 7-Day Free Trial															71.09	71.40	70.45	68.76	61.28

Competitive Comparison of Immunocore Holdings's Days Sales Outstanding

For the Biotechnology subindustry, Immunocore Holdings's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Immunocore Holdings's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immunocore Holdings's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Immunocore Holdings's Days Sales Outstanding falls into.

Save Embed

;

Save Embed

;

Immunocore Holdings Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Immunocore Holdings's Days Sales Outstanding for the fiscal year that ended in Dec. 2024 is calculated as

	Days Sales Outstanding (A: Dec. 2024 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2023 )	+	Accounts Receivable (A: Dec. 2024 ))	/	count )	/	Revenue (A: Dec. 2024 )	*	Days in Period
=	( (52.093	+	63.009)	/	2 )	/	310.202	*	365
=	57.551					/	310.202	*	365
=	67.72

Immunocore Holdings's Days Sales Outstanding for the quarter that ended in Mar. 2025 is calculated as:

	Days Sales Outstanding (Q: Mar. 2025 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2024 )	+	Accounts Receivable (A: Mar. 2025 ))	/	count )	/	Revenue (A: Mar. 2025 )	*	Days in Period
=	( (63.009	+	63.094)	/	2 )	/	93.881	*	365 / 4
=	63.0515					/	93.881	*	365 / 4
=	61.28

Immunocore Holdings (NAS:IMCR) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Immunocore Holdings Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Immunocore Holdings's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Immunocore Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunocore Holdings PLC (NAS:IMCR) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

6YG:Germany

Address

92 Park Drive, Milton Park, Abingdon, Oxfordshire, GBR, OX14 4RY

Website

https://www.immunocore.com

Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.